FDA Approves Pfizer’s Hympavzi for Treating Adults and Adolescents with Hemophilia A or B Without Inhibitors

Pfizer’s Hympavzi has received approval from the FDA for the treatment of adults and adolescents suffering from Hemophilia A or B who do not have inhibitors. This marks a significant advancement in the therapeutic options available for individuals living with these types of hemophilia, offering new hope for improved management of their condition. The approval reflects the ongoing commitment to addressing the needs of patients in the hemophilia community.